Abstract: The disclosure provides methods and compositions for the preservation of bacteria.

Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Abstract: Devices and systems disclosed herein may include a negative pressure pump that includes a reservoir defining a lumen and a longitudinal axis, a piston, and a drive assembly comprising a spring. Motion of the spring may move the piston along the longitudinal axis of the reservoir to create a negative pressure within the reservoir. Methods of manufacturing a negative pressure pump and using a negative pressure pump to remove fluid from a target site are also described.

Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Abstract: An aerosol delivery system, which includes an aerosol delivery unit, the aerosol delivery unit including: a cartridge receiver, which is configured to receive a cartridge assembly; and an inductor configured to receive the cartridge assembly and heat a liquid formulation within a capillary tube to produce an aerosol by induction heating. The cartridge assembly including an active part of the cartridge assembly including a capillary tube; a susceptor, the susceptor configured to partially surround the capillary tube; and a pair of displaceable covers, which surround at least the capillary tube and the susceptor.

Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Abstract: Devices and systems disclosed herein may include a negative pressure pump that includes a reservoir defining a lumen and a longitudinal axis, a piston, and a drive assembly comprising a spring. Motion of the spring may move the piston along the longitudinal axis of the reservoir to create a negative pressure within the reservoir. Methods of manufacturing a negative pressure pump and using a negative pressure pump to remove fluid from a target site are also described.

Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Abstract: Devices and systems disclosed herein may include a negative pressure pump that includes a reservoir defining a lumen and a longitudinal axis, a piston, and a drive assembly comprising a spring. Motion of the spring may move the piston along the longitudinal axis of the reservoir to create a negative pressure within the reservoir. Methods of manufacturing a negative pressure pump and using a negative pressure pump to remove fluid from a target site are also described.

Abstract: Injection devices with ergonomic enhancements are disclosed. Generally, the injection devices include large oversized grips, including flanges at the base end of the device for enhanced stability. Push-type and squeeze-type devices are described, as well as manual injectors and auto-injectors. Such injection devices are useful for delivering a fluid (e.g. medication) to a patient.

Abstract: An aerosol delivery system is disclosed, the system comprising: an aerosol delivery unit, the aerosol delivery unit comprising: a cartridge receiver, which is configured to receive a cartridge assembly; and an inductor configured to receive the cartridge assembly and heat a liquid formulation within a capillary tube to produce an aerosol by induction heating. The cartridge assembly including an active part of the cartridge assembly including a capillary tube; a susceptor, the susceptor configured to partially surround the capillary tube; and a pair of displaceable covers, which surround at least the capillary tube and the susceptor.

Abstract: Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample.

Abstract: Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample.

Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.